Loading
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Previous close
$3.27
−$0.11 · -3.25%
After-hours
$3.2605
−$0.0095 · -0.29%
Sep 10, 7:54 PM ET
Regular session · ET · Market data may be delayed.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Day range
Current $3.27
52-week range
Current $3.27
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
36
Expensive
Sentiment
72
Bullish
Risk
71
High Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Day range
Current $3.27
52-week range
Current $3.27
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 13.86M USD | 16.15M USD | — | — | — |
| Cost of goods sold | 2.39M USD | 475K USD | — | — | — |
| Gross profit | 11.47M USD | 15.67M USD | — | — | — |
| Research and development | 73.7M USD | 58.75M USD | 49.59M USD | 86.13M USD | 51.05M USD |
| Selling, general, and administrative | 22.19M USD | 25.42M USD | 32.61M USD | 37.35M USD | 18.66M USD |
| Operating expenses | 95.89M USD | 105.13M USD | 82.2M USD | 123.48M USD | 69.72M USD |
| Interest income | 3.61M USD | 7.04M USD | 6.63M USD | 2.76M USD | 23K USD |
| Depreciation and amortization | 4.51M USD | 2.98M USD | 1.93M USD | 709K USD | 647K USD |
| Operating income | −84.42M USD | −89.46M USD | −82.2M USD | −123.48M USD | −69.72M USD |
| Net income | −79.62M USD | −77.33M USD | −73.79M USD | −120.72M USD | −75.98M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.27M0.00%2.3T USD0.03%$373.24-0.62%
iShares Biotechnology ETFIBB1.73M0.02%10.3B USD0.44%$202.64-1.39%
Vanguard Extended Market ETFVXF1.59M0.00%93.7B USD0.05%$236.16-1.05%
iShares Micro-Cap ETFIWC559.28K0.04%1.44B USD0.60%$190.1-1.22%
Invesco Nasdaq Biotechnology ETFIBBQ13.46K0.01%97.02M USD0.19%$34.41-1.52%
ProShares Ultra Nasdaq BiotechnologyBIB7.4K0.01%98.07M USD1.19%$109.6-2.85%Vanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
